Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma

被引:5
|
作者
Rezagholizadeh, Fereshteh [1 ,2 ,3 ]
Tajik, Fatemeh [4 ]
Talebi, Morteza [1 ,5 ,6 ]
Taha, Seyed Reza [4 ]
Zadeh, Mahdieh Shariat [4 ]
Farhangnia, Pooya [3 ,7 ,8 ]
Hosseini, Hamideh Sadat [1 ]
Nazari, Aram [1 ,9 ]
Ghomi, Shabnam Mollazadeh [1 ,7 ,9 ]
Mousavi, Seyede Mahtab Kamrani [1 ,10 ]
Moghaddam, Niloofar Haeri [1 ,10 ]
Khorramdelazad, Hossein [3 ,11 ]
Joghataei, Mohammad Taghi [1 ,2 ]
Safari, Elahe [3 ,8 ]
机构
[1] Iran Univ Med Sci, Cellular & Mol Res Ctr, Tehran, Iran
[2] Iran Univ Med Sci, Fac Adv Technol Med, Dept Mol Med, Tehran, Iran
[3] Iran Univ Med Sci, Sch Med, Dept Immunol, Tehran, Iran
[4] Iran Univ Med Sci, Oncopathol Res Ctr, Tehran, Iran
[5] Iran Univ Med Sci, Fac Med, Dept Med Genet & Mol Biol, Tehran, Iran
[6] Iranian Biol Resource Ctr IBRC, Human & Anim Cell Bank, Tehran, Iran
[7] Universal Sci Educ & Res Network USERN, Immunol Board Transplantat & Cell Based Therapeut, Tehran, Iran
[8] Iran Univ Med Sci, Inst Immunol & Infect Dis, Immunol Res Ctr, Tehran, Iran
[9] Iran Univ Med Sci, Sch Med, Dept Pathol, Tehran, Iran
[10] Iran Univ Med Sci, Fac Adv Technol Med, Dept Med Nanotechnol, Tehran, Iran
[11] Rafsanjan Univ Med Sci, Sch Med, Dept Immunol, Rafsanjan, Iran
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
VISTA; PDAC; CD68; pancreatic ductal adenocarcinoma; prognosis; biomarker; CD8; IMMUNE-CHECKPOINT; POOR-PROGNOSIS; T-CELLS; EXPRESSION; CTLA-4;
D O I
10.3389/fimmu.2024.1283364
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Pancreatic cancer is a truculent disease with limited treatment options and a grim prognosis. Immunotherapy has shown promise in treating various types of cancer, but its effectiveness in pancreatic cancer has been lacking. As a result, it is crucial to identify markers associated with immunological pathways in order to improve the treatment outcomes for this deadly cancer. The purpose of this study was to investigate the diagnostic and prognostic significance of three markers, CD8, CD68, and VISTA, in pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer.Methods We analyzed gene expression data from Gene Expression Omnibus (GEO) database using bioinformatics tools. We also utilized the STRING online tool and Funrich software to study the protein-protein interactions and transcription factors associated with CD8, CD68, and VISTA. In addition, tissue microarray (TMA) and immunohistochemistry (IHC) staining were performed on 228 samples of PDAC tissue and 10 samples of normal pancreatic tissue to assess the expression levels of the markers. We then correlated these expression levels with the clinicopathological characteristics of the patients and evaluated their survival rates.Results The analysis of the GEO data revealed slightly elevated levels of VISTA in PDAC samples compared to normal tissues. However, there was a significant increase in CD68 expression and a notable reduction in CD8A expression in pancreatic cancer. Further investigation identified potential protein-protein interactions and transcription factors associated with these markers. The IHC staining of PDAC tissue samples showed an increased expression of VISTA, CD68, and CD8A in pancreatic cancer tissues. Moreover, we found correlations between the expression levels of these markers and certain clinicopathological features of the patients. Additionally, the survival analysis revealed that high expression of CD8 was associated with better disease-specific survival and progression-free survival in PDAC patients.Conclusion These findings highlight the potential of CD8, CD68, and VISTA as diagnostic and prognostic indicators in PDAC.
引用
收藏
页数:21
相关论文
共 50 条
  • [31] Prognostic and predictive value of CD163 expression and the CD163/CD68 expression ratio for response to adjuvant chemotherapy in patients with surgically resected lung squamous cell carcinoma
    Yanagawa, Naoki
    Shikanai, Shunsuke
    Sugai, Mayu
    Koike, Yoshihiko
    Asai, Toshinari
    Tanji, Takayuki
    Sugimoto, Ryo
    Osakabe, Mitsumasa
    Uesugi, Noriyuki
    Saito, Hajime
    Maemondo, Makoto
    Sugai, Tamotsu
    THORACIC CANCER, 2023, 14 (20) : 1911 - 1920
  • [32] Evaluation of CD30/CD4/CD8 in triple-negative invasive ductal carcinoma of breast in association with clinicopathological prognostic factors
    Jafarian, Amir Hossein
    Tasbandi, Aida
    Gilan, Hamed
    Sheikhi, Maryam
    Roshan, Nema Mohamadian
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2018, 61 (04) : 500 - 504
  • [33] The association between CD3+ and CD8+tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma
    Panahi, Mahshid
    Rezagholizadeh, Fereshteh
    Mollazadehghomi, Shabnam
    Farhangnia, Pooya
    Niya, Mohammad Hadi Karbalaie
    Ajdarkosh, Hossein
    Tameshkel, Fahimeh Safarnezhad
    Heshmati, Seyed Mohammad
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 35
  • [34] Overexpressions of DLL4 and CD105 are Associated with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma
    Zhou, Liangjing
    Yu, Leilai
    Ding, Guoping
    Chen, Wenchao
    Zheng, Sixin
    Cao, Liping
    PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (04) : 1141 - 1147
  • [35] Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients
    Giatromanolaki, Alexandra
    Anestopoulos, Ioannis
    Panayiotidis, Mihalis I.
    Mitrakas, Achilleas
    Pappa, Aglaia
    Koukourakis, Michael I.
    ANTICANCER RESEARCH, 2021, 41 (08) : 3989 - 3995
  • [36] Low Serum miR-607 Level as a Potential Diagnostic and Prognostic Biomarker in Patients of Pancreatic Ductal Adenocarcinoma: A Preliminary Study
    Jiang, Dawei
    Yuan, Xiangfei
    Ni, Jianqi
    Shen, Lan
    Cai, Min
    Xu, Liu
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 2021
  • [37] THE RELATIONSHIP OF TUMOUR-ASSOCIATED MACROPHAGES (CD68, CD163, CD 1 1C) AND CANCER STEM CELL (CD44) MARKERS WITH PROGNOSTIC PARAMETERS IN BREAST CARCINOMAS
    Sari, Suna
    Ozdemir, Cigdem
    Cilekar, Murat
    POLISH JOURNAL OF PATHOLOGY, 2022, 73 (04) : 303 - 309
  • [38] CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy
    Adamczyk, Agnieszka
    Niemiec, Joanna A.
    Ambicka, Aleksandra
    Mucha-Maecka, Anna
    Mitus, Jerzy
    Rys, Janusz
    JOURNAL OF MOLECULAR HISTOLOGY, 2014, 45 (01) : 35 - 45
  • [39] Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers
    Dan Calatayud
    Christian Dehlendorff
    Mogens K. Boisen
    Jane Preuss Hasselby
    Nicolai Aagaard Schultz
    Jens Werner
    Heike Immervoll
    Anders Molven
    Carsten Palnæs Hansen
    Julia S. Johansen
    Biomarker Research, 5
  • [40] Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers
    Calatayud, Dan
    Dehlendorff, Christian
    Boisen, Mogens K.
    Hasselby, Jane Preuss
    Schultz, Nicolai Aagaard
    Werner, Jens
    Immervoll, Heike
    Molven, Anders
    Hansen, Carsten Palnaes
    Johansen, Julia S.
    BIOMARKER RESEARCH, 2017, 5